|
|
Line 13: |
Line 13: |
| |Genes associated with Type 1 DM | | |Genes associated with Type 1 DM |
| | | | | |
| {| class="wikitable"
| | |
| |Genes important to type 1 diabetes pathogenesis
| |
| |Region
| |
| |Odds ratio
| |
| |Gene funtion
| |
| |-
| |
| | colspan="1" rowspan="1" |PTPN22
| |
| | colspan="1" rowspan="1" |1p13.2
| |
| | colspan="1" rowspan="1" |1·89
| |
| | colspan="1" rowspan="1" |Regulation of innate immune response, T-cell activation, and natural killer cell proliferation
| |
| |-
| |
| | colspan="1" rowspan="1" |IL10
| |
| | colspan="1" rowspan="1" |1q32.1
| |
| | colspan="1" rowspan="1" |0·86
| |
| | colspan="1" rowspan="1" |Cytokines and inflammatory response
| |
| |-
| |
| | colspan="1" rowspan="1" |AFF3
| |
| | colspan="1" rowspan="1" |2q11.2
| |
| | colspan="1" rowspan="1" |1·11
| |
| | colspan="1" rowspan="1" |Regulation of transcription
| |
| |-
| |
| | colspan="1" rowspan="1" |IFIH1
| |
| | colspan="1" rowspan="1" |2q24.2
| |
| | colspan="1" rowspan="1" |0·85
| |
| 0·85
| |
| 0·59
| |
| | colspan="1" rowspan="1" |Innate immune system NF-κB activation
| |
| |-
| |
| | colspan="1" rowspan="1" |STAT4
| |
| | colspan="1" rowspan="1" |2q32.3
| |
| | colspan="1" rowspan="1" |1·10§
| |
| | colspan="1" rowspan="1" |Cytokine-mediated signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |CTLA4
| |
| | colspan="1" rowspan="1" |2q33.2
| |
| | colspan="1" rowspan="1" |0·82
| |
| 0·84
| |
| | colspan="1" rowspan="1" |T-cell activation
| |
| |-
| |
| | colspan="1" rowspan="1" |CCR5
| |
| | colspan="1" rowspan="1" |3p21.31
| |
| | colspan="1" rowspan="1" |0·85
| |
| | colspan="1" rowspan="1" |Th1 cell development and chemokine-mediated signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |IL21, IL2
| |
| | colspan="1" rowspan="1" |4q27
| |
| | colspan="1" rowspan="1" |1·13
| |
| 1·12
| |
| 1·14
| |
| 1·15
| |
| | colspan="1" rowspan="1" |Cytokines and inflammatory response and Th1 or Th2 cell differentiation
| |
| |-
| |
| | colspan="1" rowspan="1" |IL7R
| |
| | colspan="1" rowspan="1" |5p13.2
| |
| | colspan="1" rowspan="1" |1·11
| |
| | colspan="1" rowspan="1" |T-cell-mediated cytotoxicity, immunoglobulin production, and antigen binding
| |
| |-
| |
| | colspan="1" rowspan="1" |BACH2
| |
| | colspan="1" rowspan="1" |6q15
| |
| | colspan="1" rowspan="1" |1·10
| |
| 0·88
| |
| 1·20
| |
| | colspan="1" rowspan="1" |Transcription
| |
| |-
| |
| | colspan="1" rowspan="1" |TNFAIP3
| |
| | colspan="1" rowspan="1" |6q23.3
| |
| | colspan="1" rowspan="1" |1·12
| |
| | colspan="1" rowspan="1" |Inflammatory response
| |
| |-
| |
| | colspan="1" rowspan="1" |TAGAP
| |
| | colspan="1" rowspan="1" |6q25.3
| |
| | colspan="1" rowspan="1" |0·92
| |
| | colspan="1" rowspan="1" |Signal transduction
| |
| |-
| |
| | colspan="1" rowspan="1" |IKZF1
| |
| | colspan="1" rowspan="1" |7p12.2
| |
| | colspan="1" rowspan="1" |0·89
| |
| | colspan="1" rowspan="1" |Immune-cell regulation
| |
| |-
| |
| | colspan="1" rowspan="1" |GLIS3
| |
| | colspan="1" rowspan="1" |9p24.2
| |
| | colspan="1" rowspan="1" |1·12
| |
| 1·12
| |
| 0·90
| |
| | colspan="1" rowspan="1" |Regulation of transcription
| |
| |-
| |
| | colspan="1" rowspan="1" |IL2RA
| |
| | colspan="1" rowspan="1" |10p15.1
| |
| | colspan="1" rowspan="1" |1·20
| |
| 0·73
| |
| 0·52
| |
| 0·62
| |
| 0·82
| |
| | colspan="1" rowspan="1" |Alternative mRNA splicing Th1 or Th2 cell differentiation
| |
| |-
| |
| | colspan="1" rowspan="1" |PRKCQ
| |
| | colspan="1" rowspan="1" |10p15.1
| |
| | colspan="1" rowspan="1" |0·69
| |
| | colspan="1" rowspan="1" |Apoptotic process, inflammatory response, innate immune response, and T-cell-receptor signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |NRP1
| |
| | colspan="1" rowspan="1" |10p11.22
| |
| | colspan="1" rowspan="1" |1·11
| |
| | colspan="1" rowspan="1" |Signal transduction
| |
| |-
| |
| | colspan="1" rowspan="1" |INS
| |
| | colspan="1" rowspan="1" |11p15.5
| |
| | colspan="1" rowspan="1" |0·42
| |
| 0·63
| |
| 0·63
| |
| | colspan="1" rowspan="1" |Insulin signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |BAD
| |
| | colspan="1" rowspan="1" |11q13.1
| |
| | colspan="1" rowspan="1" |0·92
| |
| | colspan="1" rowspan="1" |Apoptosis
| |
| |-
| |
| | colspan="1" rowspan="1" |CD69
| |
| | colspan="1" rowspan="1" |12p13.31
| |
| | colspan="1" rowspan="1" |0·87
| |
| 1·10
| |
| | colspan="1" rowspan="1" |Signal transduction
| |
| |-
| |
| | colspan="1" rowspan="1" |ITGB7
| |
| | colspan="1" rowspan="1" |12q13.13
| |
| | colspan="1" rowspan="1" |1·19
| |
| | colspan="1" rowspan="1" |Response to virus and regulation of immune response
| |
| |-
| |
| | colspan="1" rowspan="1" |ERBB3
| |
| | colspan="1" rowspan="1" |12q13.2
| |
| | colspan="1" rowspan="1" |1·25
| |
| | colspan="1" rowspan="1" |Regulation of transcription, innate immune response, and lipid metabolism
| |
| |-
| |
| | colspan="1" rowspan="1" |CYP27B1
| |
| | colspan="1" rowspan="1" |12q14.1
| |
| | colspan="1" rowspan="1" |0·82
| |
| | colspan="1" rowspan="1" |Metabolism of lipids, lipoproteins, steroid hormones, and vitamin D
| |
| |-
| |
| | colspan="1" rowspan="1" |SH2B3
| |
| | colspan="1" rowspan="1" |12q24.12
| |
| | colspan="1" rowspan="1" |1·24
| |
| 0·76
| |
| 0·76
| |
| | colspan="1" rowspan="1" |Signal transduction
| |
| |-
| |
| | colspan="1" rowspan="1" |GPR183
| |
| | colspan="1" rowspan="1" |13q32.3
| |
| | colspan="1" rowspan="1" |1·12
| |
| | colspan="1" rowspan="1" |Humoral immune response
| |
| |-
| |
| | colspan="1" rowspan="1" |DLK1
| |
| | colspan="1" rowspan="1" |14q32.2
| |
| | colspan="1" rowspan="1" |0·88
| |
| 0·90
| |
| | colspan="1" rowspan="1" |Regulation of gene expression
| |
| |-
| |
| | colspan="1" rowspan="1" |RASGRP1
| |
| | colspan="1" rowspan="1" |15q14
| |
| | colspan="1" rowspan="1" |0·85
| |
| 1·15
| |
| | colspan="1" rowspan="1" |Inflammatory response to antigenic stimulus and cytokine production
| |
| |-
| |
| | colspan="1" rowspan="1" |CTSH
| |
| | colspan="1" rowspan="1" |15q25.1
| |
| | colspan="1" rowspan="1" |0·81
| |
| 0·78
| |
| 0·90
| |
| | colspan="1" rowspan="1" |Immune response-regulating signalling pathway T-cell-mediated cytotoxicity adaptive immune response
| |
| |-
| |
| | colspan="1" rowspan="1" |CLEC16A
| |
| | colspan="1" rowspan="1" |16p13.13
| |
| | colspan="1" rowspan="1" |0·83
| |
| 0·82
| |
| 1·14
| |
| | colspan="1" rowspan="1" |Unknown
| |
| |-
| |
| | colspan="1" rowspan="1" |IL27
| |
| | colspan="1" rowspan="1" |16p11.2
| |
| | colspan="1" rowspan="1" |1·19
| |
| 0·90
| |
| 1·24
| |
| | colspan="1" rowspan="1" |Inflammatory response and regulation of defence response to virus
| |
| |-
| |
| | colspan="1" rowspan="1" |ORMDL3
| |
| | colspan="1" rowspan="1" |17q12
| |
| | colspan="1" rowspan="1" |0·90
| |
| | colspan="1" rowspan="1" |Protein binding
| |
| |-
| |
| | colspan="1" rowspan="1" |PTPN2
| |
| | colspan="1" rowspan="1" |18p11.21
| |
| | colspan="1" rowspan="1" |1·20
| |
| | colspan="1" rowspan="1" |Cytokine signalling and B-cell and T-cell differentiation
| |
| |-
| |
| | colspan="1" rowspan="1" |CD226
| |
| | colspan="1" rowspan="1" |18q22.2
| |
| | colspan="1" rowspan="1" |1·13
| |
| | colspan="1" rowspan="1" |Immunoregulation and adaptive immune system
| |
| |-
| |
| | colspan="1" rowspan="1" |TYK2
| |
| | colspan="1" rowspan="1" |19p13.2
| |
| | colspan="1" rowspan="1" |0·82
| |
| 0·87
| |
| 0·67
| |
| | colspan="1" rowspan="1" |Cytokine-mediated signalling pathway, intracellular signal transduction, and type I interferon signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |FUT2
| |
| | colspan="1" rowspan="1" |19q13.33
| |
| | colspan="1" rowspan="1" |0·87
| |
| 0·75
| |
| 0·87
| |
| | colspan="1" rowspan="1" |Metabolic pathways
| |
| |-
| |
| | colspan="1" rowspan="1" |UBASH3A
| |
| | colspan="1" rowspan="1" |21q22.3
| |
| | colspan="1" rowspan="1" |1·16
| |
| | colspan="1" rowspan="1" |Regulation of cytokine production
| |
| Regulation of T-cell receptor signalling pathway
| |
| |-
| |
| | colspan="1" rowspan="1" |C1QTNF6
| |
| | colspan="1" rowspan="1" |22q12.3
| |
| | colspan="1" rowspan="1" |1·11
| |
| | colspan="1" rowspan="1" |B-cell receptor signalling pathway, chemokine signalling pathway, and natural killer cell-mediated cytotoxicity
| |
| |}
| |
| | | | | |
| | | | | |